Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for treatment-resistant major depressive disorder
IRCT20210806052096N1Phase 2Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by Zanjan University of Medical Sciences. Started Apr 2022; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20210806052096N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210806052096N1.